A Rare Pathogen Comamonas Testosteroni: A Case Report And Review of The Literature

S. Gayenur Buyukberber (gynrb@gmail.com)
Ankara City Hospital: Ankara Sehir Hastanesi  https://orcid.org/0000-0002-1745-0388

Ipek Mumcuoglu
Ankara City Hospital: Ankara Sehir Hastanesi

B. Orkun Ozbay
Ankara City Hospital: Ankara Sehir Hastanesi

Adalet Aypak
Ankara City Hospital: Ankara Sehir Hastanesi

Bedia Dinc
Ankara City Hospital: Ankara Sehir Hastanesi

Research Article

Keywords: aerobic, motile, non-spore-forming bacillus, testosteroni, Microorganism

Posted Date: July 14th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-532104/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at SN Comprehensive Clinical Medicine on June 15th, 2023. See the published version at https://doi.org/10.1007/s42399-023-01505-0.
Abstract

Comamonas testosteroni is a Gram-negative, aerobic, motile, non-spore-forming bacillus. It has not been recognized as a component of the endogenous human microflora. Due to its ability to survive in liquid environments, it can survive for a long time in a hospital environment and cause opportunistic infections. Although rare, C. testosteroni has been reported as a cause of cellulitis, peritonitis, endocarditis, meningitis, endophthalmitis, tenosynovitis, pneumonia and bacteremia. Here, we present a case of a 4-year-old girl who was operated on for persistent cloaca with C. testosteroni isolated in her urine culture. Identification studies were performed by MALDI-TOF MS (bioMérieux, France) mass spectrophotometer method. Antibiotic susceptibility tests were performed with the automatic device VITEK-2 Compact (bioMérieux, France). Microorganism was found susceptible to ceftazidime and ciprofloxacin; intermediate susceptible to meropenem and piperacillin / tazobactam and resistant to gentamicin, amikacin, imipenem and trimethoprim-sulfamethoxazole. With this case report, C. testosteroni was reported as the first cause of urinary tract infection in our country and the third in the world.

Introduction

Comamonas testosteroni, formerly known as Pseudomonas testosteroni, is a gram-negative, aerobic, motile, non-fermentative and non-spore forming bacillus [7]. The name "Testosteroni" comes from the bacteria's ability to use the carbon in testosterone metabolism, as is observed in some types of Pseudomonas and fungi [10]. C. testosteroni is commonly found in soil, water, plants, animals and waste all over the world and is considered as an environmental microorganism which is not defined as a human endogenous microflora element [6, 7]. Because of its ability to live in liquid environments, this organism is seen as an opportunistic nosocomial pathogen in hospitals and intensive care units. It grows well on routine bacteriologic media such as sheep blood agar and chocolate agar [7]. The need for minimal nutrients to grow even in distilled water and adaptation to different physical conditions leads to its important role as an opportunistic pathogen in hospitals. Since it became clinically important; it has been reported in publications as a causative agent of cellulitis, peritonitis, endocarditis, meningitis, endophthalmitis, tenosynovitis, pneumonia and bacteremia [10].

Case Report

A 4-year-old girl with frequent urinary incontinence and recurrent urinary tract infection despite taking prophylaxis has applied to our hospital for further examination. She was operated two years ago due to persistent cloaca, a total urogenital mobilization was performed, and postoperative uterus, vagina, and partial bladder necrosis occurred. She has a colostomy in the left lower quadrant, and has frequent urinary incontinence and recurrent urinary tract infection despite taking prophylaxis.

Urinalysis report was; leukocyte 14 p/HPF, leukocyte esterase ++, bacteria were trace and others were found within normal limits. Colonies grown on blood and MacConkey agar, incubated at 35–37°C, were identified as 99% probability C. testosteroni by mass spectrometry method MALDI-TOF MS (bioMérieux, France). Antibiotic susceptibility tests were performed with the automatic device of VITEK-2 Compact (bioMérieux, France) and interpreted in accordance with EUCAST criteria and it was susceptible to ceftazidime, ciprofloxacin; intermediate susceptible to meropenem, piperacillin / tazobactam; resistant to gentamicin, amikacin, imipenem, trimethoprim-sulfamethoxazole. Ceftazidime was added to the treatment of the patient who was already treated with amikacin. There was no growth in the control urine culture performed after 5 days of treatment. And then the patient was discharged with cure. The increase in pathogenicity and antibiotic resistance of C. testosteroni once again demonstrates the importance of rational antibiotic use. With this case report, C. testosteroni was reported as the first cause of urinary tract infection in our country and the third in the world.

Discussion

C. testosteroni which was first reported in 1975, is an infection agent in samples such as cerebrospinal fluid, abdominal abscess and appendix tissue, most commonly from blood and peritoneal fluid [Table 1]. Most of the previously reported cases were immunodeficient due to malignancy, diabetes mellitus, chronic liver disease, and end-stage renal disease [10]. The agent is most frequently isolated from the blood (20 cases), followed by peritoneal fluid (9 cases), cerebrospinal fluid (3 cases) and urine (2 cases). There are rare cases in which the agent was isolated from cord fluid, respiratory secretions, deep tracheal aspirate, abdominal abscess, bite site tissue (animal bite), aortic valve, appendicitis, stool and vitreous fluid. Appendicitis is found to be the most common predisposing factor in cases detecting C. testosteroni in peritoneal fluid. Although bacteria is not an endogenous flora element, the isolation of a large number of patients with perforated appendicitis (7 out of 9 cases) made us think that this microorganism could create a unique location in the appendix [1].

Table 1. Comamonas testosterone-induced infection cases in the literature.
| No | Age / Gender | Specimens isolated | Predisposing factor | Antibiotic therapy | Outcome | References |
|----|--------------|---------------------|---------------------|--------------------|---------|------------|
| 1  | 31/F         | blood               | rheumatic heart disease | kanamycin, tetracycline | recovered | Atkinson et al. (1975) [4] |
| 2  | 31/M         | abdominal abscess drainage fluid | perforated appendicitis | cefoxitin, ampicillin then drainage, gentamicin, clindamycin | recovered | Barbaro et al. (1987) [5] |
| 3  | 24/F         | cerebrospinal fluid | intravenous drug abuse | moxalectam, nafcillin | recovered | Barbaro et al. (1987) [5] |
| 4  | 59/F         | peritoneal fluid    | alcoholic cirrhosis   | cefoxitin          | recovered | Barbaro et al. (1987) [5] |
| 5  | 11/M         | peritoneal fluid    | perforated appendicitis | ampicillin, clindamycin, tobramycin | recovered | Barbaro et al. (1987) [5] |
| 6  | 12/F         | peritoneal fluid    | perforated appendicitis | cefoxitin         | recovered | Barbaro et al. (1987) [5] |
| 7  | 21/F         | peritoneal fluid    | perforated appendicitis, pregnancy | cefoxitin | recovered | Barbaro et al. (1987) [5] |
| 8  | Stillborn    | Cord fluid          | maternal intravenous drug abuse | could not be cured due to death | dead | Barbaro et al. (1987) [5] |
| 9  | 84/F         | urine               | congestive heart failure | ampicillin        | recovered | Barbaro et al. (1987) [5] |
| 10 | Newborn      | blood               | maternal intravenous drug abuse, prematurity | ampicillin | dead | Barbaro et al. (1987) [5] |
| 11 | 17/F         | peritoneal fluid    | appendicitis          | no data            | recovered | Barbaro et al. (1987) [5] |
| 12 | 59/M         | no data             | no data              | no data            | recovered | Barbaro et al. (1987) [5] |
| 13 | 66/M         | peritoneal fluid    | no data              | no data            | recovered | Barbaro et al. (1987) [5] |
| 14 | 14/M         | appendix             | appendicitis         | no data            | recovered | Barbaro et al. (1987) [5] |
| 15 | 15/M         | peritoneal fluid    | no data              | no data            | recovered | Barbaro et al. (1987) [5] |
| 16 | 4/M          | blood               | no data              | no data            | recovered | Barbaro et al. (1987) [5] |
| 17 | 28/M         | blood               | no data              | no data            | recovered | Barbaro et al. (1987) [5] |
| 18 | 24/M         | peritoneal fluid    | perforated appendicitis | cefoxitin | recovered | Barbaro et al. (1987) [5] |
| 19 | No data      | respiratory secretions | AIDS-related complex | ceftazidime      | recovered | Franzetti et al. (1992) |
| 20 | 35/M         | animal bite tissue  | zoonotic infection   | ceftazidime, gentamicin | recovered | Isolato et al. (2000) |
| 21 | 75/F         | blood, central venous catheter | cancer central venous catheter | ceftazidime, gentamicin | recovered | Le Moal et al. (2001) |
| 22 | 89/M         | blood               | advanced age         | levofloxacin      | recovered | Smith et al. (2003) |
| 23 | 50/M         | cerebrospinal fluid | cholesteatoma        | meropenem         | recovered | Arda et al. (2003) [3] |
| 24 | 49/M         | Blood, mitral valve | infective endocarditis | cefepime, gentamicin then ampicillin and surgery | recovered | Cooper et al. (2005) |
| 25 | 22/M         | blood, peritoneal fluid | perforated appendicitis | cefazolin       | recovered | Gul et al. (2007) [8] |
| 26 | 54/F         | blood               | chemotherapy, central venous catheter | cefepime, ciprofloxacin | recovered | Abraham et al. (2007) [1] |
| 27 | 54/M         | cerebrospinal fluid | chronic alcoholic car accident | no data | dead | Jin et al. (2008) |
| 28 | 82/F         | vitreous biopsy     | advanced age, diabetes | ceftazidime, ciprofloxacin | recovered | Reddy et al (2009) [13] |
| Patient ID | Age | Sex | Site of Infection | Underlying Condition | Antibiotic Treatment | Outcome | Reference |
|------------|-----|-----|-------------------|----------------------|---------------------|---------|-----------|
| 29         | 83  | M   | Blood             | Advanced age, ischemic cerebrovascular accident | Amikacin, Piperacillin / Tazobactam | Recovered | Katircioglu et al (2010) [9] |
| 30         | 64  | F   | Blood             | Hemodialysis         | No data             | Recovered | Nseir et al. (2011) |
| 31         | 54  | M   | Blood             | Foot injury          | Oxacillin, Flomoxef then Ciprofloxacin | Recovered | Tsui et al. (2011) [15] |
| 32         | 73  | M   | Blood             | Hepatocellular cancer, Chronic Hepatitis B | Metasin, Gentamicin followed by Levofloxacin | Recovered | Tsui et al. (2011) [15] |
| 33         | 10  | M   | Endotracheal Aspirate | Cerebral Palsy, Tracheostomy | Ceftriaxone, Clarithromycin | Recovered | Ozden et al. (2011) [11] |
| 34         | 10  | M   | Blood             | Medullablastoma, Chemotherapy | Ciprofloxacin, Amikacin | Recovered | Farshad et al. (2012) |
| 35         | 19  | F   | Blood             | Osteosarcoma         | Imipenem, Vancomycin, Ciprofloxacin | Recovered | Farshad et al. (2012) |
| 36         | 16  | M   | Peritoneal Fluid  | Perforated Appendicitis | Amikacin, Ampicillin, Clindamycin | Recovered | Bayhan et al. (2013) [6] |
| 37         | 80  | F   | Blood             | Diabetes             | Cefazolin, Doripenem | Recovered | Orsini et al. (2014) [10] |
| 38         | 51  | M   | Aortic Valve      | No                   | Ciprofloxacin        | Recovered | Duran et al. (2015) [7] |
| 39         | 42  | F   | Blood             | Septic Shock         | Ceftazidine and Levofloxacin | Recovered | Who et al. (2015) |
| 40         | 62  | M   | Blood             | Diabetes, Ischemic Cerebrovascular Accident | Could not be cured due to death | Dead | Pekinturk N., Akgunes A. (2016) [12] |
| 41         | 1   | F   | Blood             | Acute Gastroenteritis, Sepsis | Ceftriaxone | Recovered | Ruziaki W., Hashami H. (2017) [14] |
| 42         | 65  | F   | Stool             | Acute Gastroenteritis, Cholelithiasis | Ciprofloxacin | Recovered | Farooq S. et al. (2017) |
| 43         | 30  | F   | Blood             | Neutropenia          | Moxifloxacin        | Recovered | Akhtar et al. (2018) [2] |
| 44         | 46  | F   | Blood and Urine   | Sepsis               | Gentamicin and Imipenem | Recovered | Tiwari S et al. (2019) |
| 45         | 4   | F   | Urine             | Persistent Cloaca    | Ceftazidime, Amikacin | Recovered | This case |

Eight *C. testosteroni* cases have been reported in Turkey so far. The first case was purulent meningitis in a patient with recurrent cholesteatoma reported by Arda et al. in 2003. The microorganism was isolated from the cerebrospinal fluid and treated with meropenem [3].

The second case was *C. testosteroni* bacteremia in a patient with perforated acute appendicitis. It was isolated from the patient's peritoneal fluid and blood cultures by Gul et al. in 2007. It had been treated with cefazolin [8].

The third case was reported in 2010 by Katircioglu et al. It was a case of bacteremia in an intensive care patient. This case isolated from blood cultures was the first case that showed the development of multiple antibiotic resistance including imipenem [9].

The fourth case was the pneumonia case in an intensive care patient reported by Ozden et al. in 2011. Microorganism isolated from endotracheal aspirate culture was found susceptible to amikacin, imipenem, levofloxacin, meropenem, netilmicin, piperacillin-tazobactam, cefazidime, cefepime, tigecycline, trimethoprim-sulfamethoxazole and resistant to aztreonam, colistin, gentamicin, ciprofloxacin and tetracycline [11].

The fifth case was reported by Bayhan et al. in 2013. It was a case of 16-year-old perforated appendicitis with the complaints of acute abdominal pain, vomiting and constipation. The microorganism isolated from the peritoneal fluid was found susceptible to ampicillin, ampicillin-sulbactam, cefazidime, cefazolin, gentamicin, amikacin, ciprofloxacin, imipenem, piperacillin and resistant to ceftriaxone, cefuroxime and trimethoprim-sulfamethoxazole. It was treated with amikacin, ampicillin and clindamycin [6].

The sixth case was an endocarditis case reported by Duran et al. in 2015. The microorganism isolated from the aortic valve was resistant to piperacillin-tazobactam, imipenem, meropenem, gentamicin and netilmicin and was treated with ciprofloxacin [7].

The seventh case was *C. testosteroni* bacteremia, isolated from the blood cultures of a patient with diabetes and hemiplegia reported by Pekinturk et al. in 2016. The microorganism was found resistant to aztreonam and colistin [12].

The eighth case was the bacteremia due to *C. testosteroni* grown in the blood culture of a patient with neutropenia who presented with high fever reported by Akhtar et al. in 2018. Cefixime and Ceftazidime resistant microorganism was treated with moxifloxacin [2].
Although *C. testosteroni* can survive for a long time in hospital environments, *C. testosteroni* infections are community acquired [7]. Gastrointestinal pathologies are often accompanied by intraabdominal infections, and these infections are the most commonly reported group of infections. Risk factors that may cause infections in other cases are the use of central venous catheters, drug injections, skin cuts and subcutaneous lacerations, and surgical procedures [8].

*C. testosteroni* infections rarely cause death and mostly respond well to antibiotic therapy. In the reported cases, it was susceptible to aminoglycosides, fluoroquinolones, carbapenems, piperacillin-tazobactam, most cephalosporins and trimethoprim-sulfamethoxazole [3, 15]. However, it should be kept in mind that antibiotic resistance has increased over the years and the resistance profile may change. *C. testosteroni* was reported resistant to aminoglycosides in 2009, and resistant to aminoglycosides, carbapenems and piperacillin-tazobactam in 2015 [7, 15].

The strain isolated in this case; was found susceptible to ceftazidime (2.0 mg/L), ciprofloxacin ($\leq$ 0.25 mg/L), intermediate susceptible to meropenem (8.0 mg/L), piperacillin / tazobactam (64.0 mg/L), resistant to gentamicin ($\geq$ 16.0 mg/L), amikacin ($\geq$ 64.0 mg/L), imipenem ($\geq$ 16.0 mg/L), trimethoprim-sulfamethoxazole (80.0 mg/L). Our patient's urogenital disorder and multiple surgical interventions in this case were predisposing factors for infection. The isolate in our case was found susceptible to ceftazidime and ciprofloxacin, while it was resistant to preparations such as carbapenem and piperacilin-tazobactam, suggesting that it was an infectious agent in the hospital environment due to the widespread use of broad-spectrum antibiotics. With this case report, a rare pathogen was drawn to attention; the importance of rational antibiotic use and the contribution of accurate and rapid diagnosis of microorganisms to treatment with new technologies have been emphasized.

**Declarations**

**Funding**

Not applicable.

**Conflict of Interest**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethics Approval**

1. All procedures performed were under the institutional and/or national research committee's ethical standards and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This report was supervised and approved by the Ankara City Hospital No.1 clinical research Ethics Committee. (reference no:E1/1539/2021)

**Consent to Participate**

Not applicable.

**Consent for Publication**

Approved by the ethical committee.

**Data and Materials Availability**

Is available if required.

**Code Availability**

Not applicable.

**Contributions**

All authors contributed to the development of the manuscript. Literature review and manuscript writing were done by Dr. S.Gayenur Büyükberber. All authors read and approved the final manuscript.

**Corresponding author**

Correspondence to S.Gayenur Büyükberber (gynrbb@gmail.com)

Department of Medical Microbiology, Ankara City Hospital, Ankara, Turkey.

**Author information**

**Affiliations**

Sevim Gayenur Buyukberber (gynrbb@gmail.com)
References

1. Abraham JM, Simon GL. Comamonas testosterone Bacteremia: A case report and review of the literature. Infect Dis Clin Pract. 2007;15:272–3.

2. Aktar Samanci G, Ayaydin Z, Rahmanali Onur A, Gür Vural D, Clean H. An Isolated Bacterium Factor: Comamonas testosterone Turkish Microbiole. Cem Derg. 2018;48(2):147–51. 10.5222/TMCD.2018.147. Case Report doi.

3. Arda B, Aydemir S, Yamazhan T, Hassaan, A, Tunger A, Serter D. Comamonas testosteroni meningitis in a patient with recurrent cholesteatoma. Acta Pathol Microbim Immunol Scand. 2003;111:474–6.

4. Atkinson BE, Smith DL, Lockwood WR. Pseudomonas testosterone septicemia. Ann Intern Medicine. 1975;83:369–70.

5. Barbaro DJ, Mackowiak PA, Barth SS. Pseudomonas testosterone infections: Eighteen recent cases and a review of the literature. Southern PM Jr Rev Infect Dis. 1987;9:124–9.

6. Bayhan GI, Tanir G, Karaman I, et al. Comamonas testosteroni: An unusual bacteria associated with acute appendicitis. Balkan Medical Journal. 2013;30:447–8.

7. Duran A, Abacilar AF, Uyar IS, et al. Comamonas testosterone endocarditis in Turkey: A case report and review of the literature. International Medical Journal of Sifa University. 2015;2(2):44–7.

8. Gul M, Ciragil P, Bulbuloglu E, Aral M, Alkis S, Ezberci F. Comamonas testosterone bacteremia in a patient with perforated acute appendicitis. Acta Microbiol Immunol Hung. 2007;54:317–21.

9. Katircioğlu K, Ozkalkanli MY, Yurtsever SG, et al. Comamonas testosteroni infection in intensive care patient. Turk Anest Rean Der Dergisi. 2010;38:129–32.

10. Orsini J, Tam E, Hauser N, et al. (2014). Polymicrobial bacteremia involving Comamonas testosterone. Case reports in medicine. Makale ID: 578127. http://doi.org/10.1155/2014/578127.

11. Ozden S, Kocturk SA, Guler S, Kilinc D. Comamonas testosteroni infection in intensive care patient.1st National Congress of Clinical Microbiology. Turkey: Antalya; 2011. p. 107.

12. Pekinturk N, Akgunes A. A Rare Pathogen Comamonas Testosterone: Case Report and Review of the Literature. Kocaeli University Journal of Health Sciences. 2016;2(3):7–10.

13. Reddy AK, Murthy SI, Jalali S, Gopinathan U. Post-operative endophthalmitis due to an unusual pathogen, Comamonas testosterone. J Med Microbiol. 2009;58(3):374–5. doi:10.1099/jmm.0.006072-0.

14. Ruziaki WA, Hashami HA. Unusual Pathogen Comamonas testosterone Sepsis Following Gastroenteritis in a 12 Months Old Child: Case Report and Literature Review. American Journal of Medical Case Reports. 2017;5(6):148–50.

15. Tsui TL, Tsao S-M, Liu K-S, et al. Comamonas testosteroni infection in Taiwan: reported two cases and literature review. Journal of Microbiology Immunology Infection. 2011;44(1):67–71.